Zenith Capital (Zenith Capital) Change In Prepaid Assets : $0.00 Mil (TTM As of . 20)

View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Change In Prepaid Assets?

Zenith Capital's Change In Prepaid Assets for the quarter that ended in . 20 was $0.00 Mil. It means Zenith Capital's Prepaid Assets stayed the same from . 20 to . 20 .

Zenith Capital's Change In Prepaid Assets for the fiscal year that ended in . 20 was $0.00 Mil. It means Zenith Capital's Prepaid Assets stayed the same from . 20 to . 20 .

Zenith Capital Change In Prepaid Assets Historical Data

The historical data trend for Zenith Capital's Change In Prepaid Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Change In Prepaid Assets Chart

Zenith Capital Annual Data

Trend

Change In Prepaid Assets

Zenith Capital Quarterly Data

Change In Prepaid Assets

Zenith Capital Change In Prepaid Assets Calculation

Change In Prepaid Assets is any increase or decrease between periods of the prepaid assets.

Change In Prepaid Assets for the trailing twelve months (TTM) ended in . 20 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Zenith Capital Change In Prepaid Assets Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Change In Prepaid Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Change In Prepaid Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1

Website

Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines